Geovax announces expansion of next-generation covid-19 vaccine rights to include omicron variants and use against orthopoxviruses

Expanded rights include development of geo-cm04s1 against mpox (monkeypox) and smallpox atlanta, ga, april 17, 2023 (globe newswire) -- via newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the expansion of its rights under its exclusive license agreement with city of hope (coh), a world-renowned cancer research and treatment organization, to include development and commercialization rights against orthopoxviruses in addition to sars-cov-2. the original license agreement with coh provides geovax exclusive worldwide rights to key patents, including the use of coh's proprietary synthetic mva (smva) process, for developing covid-19 vaccines, including geo-cm04s1 (cm04s1), a multi-antigenic sars-cov-2 investigational vaccine expressing the spike and nucleocapsid antigens of the sars-cov-2 virus.
GOVX Ratings Summary
GOVX Quant Ranking